European Medicines Agency approves abiraterone combined with hormone therapy as first-line treatment for advanced prostate cancer

22 Nov 2017
The Institute of Cancer Research

The prostate cancer drug abiraterone has been approved by the European Medicines Agencyin combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer. Men with newly diagnosed prostate tumours that are ‘high risk’ or have already spread will be eligible for the combination, which was shown to delay progression of the disease by over a year longer than standard hormone treatment alone.


Click here to read 'The Institute of Cancer Research' news article in full